Treatment with antidepressants and lithium is associated with increased risk of treatment with antiparkinson drugs: A pharmacoepidemiological study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 6, 2006, Pages 781-783

  Brandt Christensen, M ^a,b   Kvist, K ^b   Nilsson, F M ^c   Andersen, P K ^b   Kessing, L V ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIPARKINSON AGENT; LITHIUM; LITHIUM CARBONATE; TRANQUILIZER;

ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DENMARK; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; CASE CONTROL STUDY; EPIDEMIOLOGY; PATHOPHYSIOLOGY; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; RISK FACTOR; STATISTICS;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPARKINSON AGENTS; ANXIETY DISORDERS; CASE-CONTROL STUDIES; DENMARK; EPIDEMIOLOGIC STUDIES; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; MOOD DISORDERS; PARKINSON DISEASE; PHARMACOEPIDEMIOLOGY; PRESCRIPTIONS, DRUG; RISK FACTORS;

EID: 33646822433     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2005.083345     Document Type: Article

References (18)

1. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;149:443-54.
2. Kanner AM. Depression and the risk of neurological disorders. Lancet 2005;366:1147-8.
3. Aarsland D, Cummings JL. Depression in Parkinson's disease. Acta Psychiatr Scand 2002;106:161-2.
4. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000;15:669-77.
5. Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 2001;104:380-6.
6. Leentjens AF, van den AM, Metsemakers JF, et al. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003;18:414-18.
7. Schuurman AG, van den AM, Ensinck KT, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002;58:1501-4.
8. World Health Organisation Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs. Oslo: WHO, 2003.
9. Schmidt AC. Antiviral therapy for influenza: a clinical and economic comparative review. Drugs 2004;64:2031-46.
10. Claxton AJ, Li Z, McKendrick J. Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. Br J Psychiatry 2000;177:163-8.
11. Littner MR, Kushida C, Anderson WM, et al. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27:557-9.
12. Berkson, J. Limitations of the applicance of fourfold table analysis to hospital data. Biometric Bull 1946;2:126-35.
13. Lukovits TG, Mazzone TM, Gorelick TM. Diabetes mellitus and cerebrovascular disease. Neuroepidemiology 1999;18:1-14.
14. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003;160:1516-18.
15. Chuang DM, Chen RW, Chalecka-Franaszek E, et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002;4:129-36.
16. Xu J, Culman J, Blume A, et al. Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Stroke 2003;34:1287-92.
17. Manji HK, Moore GJ, Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 1999;46:929-40.
18. Mayeux R. The "serotonin hypothesis" for depression in Parkinson's disease. Adv Neurol 1990;53:163-6.